[D] Kazia Therapeutics Limited American SEC Filing

Rhea-AI Filing Summary

Kazia Therapeutics Ltd filed a Form D reporting a Regulation D, Rule 506(b) offering that raised $2,050,013, with $2,050,013 sold and $0 remaining. The filing lists four investors and identifies offered securities as equity, options/warrants, and securities issuable on exercise.

The notice discloses pre-funded warrants to purchase up to 204,547 ADSs, each ADS representing 500 ordinary shares, and each pre-funded warrant exercisable for one ADS at an exercise price of $0.0001 per ADS. The filing reports $0 in sales commissions and finders' fees, $0 of proceeds paid to named officers or directors, and was signed by CEO John Friend on 2025-08-14.

Positive

• Offering fully subscribed: Total offering amount of $2,050,013 was sold with $0 remaining.
• No sales commissions or finders' fees: The filing reports $0 for sales commissions and finders' fees.
• No proceeds paid to named officers or directors: Item 16 reports $0 used for payments to listed executives or directors.

Negative

• Potential dilution from pre-funded warrants: Warrants cover up to 204,547 ADSs, each ADS representing 500 ordinary shares, exercisable at $0.0001 per ADS.
• Investor concentration: Only 4 investors participated, indicating concentration risk.
• Issuer size not disclosed: The issuer elected to decline to disclose revenue and aggregate net asset value ranges.

Insights

Securities Analyst

TL;DR: A small Rule 506(b) financing of $2.05M was completed via ADS-linked pre-funded warrants, sold to four investors.

The financing raises working capital with no commissions reported and no proceeds allocated to named executives, which preserves gross proceeds for corporate use. The structure includes pre-funded warrants for ADSs and an extremely low exercise price of $0.0001 per ADS, which will effectively convert into equity at a nominal cash cost to warrant holders. Concentration with only four investors and the ADS structure are material elements investors should note when assessing dilution and shareholder base changes.

Corporate Governance Expert

TL;DR: Routine Regulation D disclosure; governance details are limited but factual about fees, use of proceeds, and signatory.

The Form D confirms no sales commissions or finders' fees and no payments to named officers or directors, which is a clear, favorable disclosure for governance transparency. The issuer declined to disclose size metrics, which limits contextual assessment of the offering relative to company scale. The filing is signed by the CEO, indicating authorized corporate approval for the offering.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number:			3235-0076
Estimated average burden
hours per response:			4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names

None

Entity Type

0001075880

NOVOGEN LTD

X	Corporation
	Limited Partnership
	Limited Liability Company
	General Partnership
	Business Trust
	Other (Specify)

Name of Issuer

KAZIA THERAPEUTICS LTD

Jurisdiction of Incorporation/Organization

AUSTRALIA

Year of Incorporation/Organization

X	Over Five Years Ago
	Within Last Five Years (Specify Year)
	Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
KAZIA THERAPEUTICS LTD
Street Address 1		Street Address 2
THREE INTERNATIONAL TOWERS LEVEL 24,		300 BARANGAROO AVENUE
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SYDNEY NSW	AUSTRALIA	2000	01161298780088

3. Related Persons

Last Name	First Name	Middle Name
Friend	John
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Carmine	Bryce
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Coffey	Steven
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Davidson	Ebru
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Apple	Robert
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Bonacorda	Jeffrey
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Hansen	Elissa
Street Address 1	Street Address 2
Level 24, Three International Towers	300 Barangaroo Avenue
City	State/Province/Country	ZIP/PostalCode
Sydney	AUSTRALIA	2000

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Banking & Financial Services

Commercial Banking

Insurance

Investing

Investment Banking

Pooled Investment Fund

Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

	Health Care
	X Biotechnology
	Health Insurance
	Hospitals & Physicians
	Pharmaceuticals
	Other Health Care
	Manufacturing
	Real Estate
	Commercial
	Construction
	REITS & Finance
	Residential
	Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

Other Technology

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range		OR	Aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	$1 - $1,000,000			$1 - $5,000,000
	$1,000,001 - $5,000,000			$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000			$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000			$50,000,001 - $100,000,000
	Over $100,000,000			Over $100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

		Rule 504(b)(1) (not (i), (ii) or (iii))
		Rule 504 (b)(1)(i)
		Rule 504 (b)(1)(ii)
		Rule 504 (b)(1)(iii)
	X	Rule 506(b)
		Rule 506(c)
		Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)

Section 3(c)(1) Section 3(c)(9)

Section 3(c)(2) Section 3(c)(10)

Section 3(c)(3) Section 3(c)(11)

Section 3(c)(4) Section 3(c)(12)

Section 3(c)(5) Section 3(c)(13)

Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X	New Notice			Date of First Sale	2025-08-04				First Sale Yet to Occur
	Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X	Equity		Pooled Investment Fund Interests
	Debt		Tenant-in-Common Securities
X	Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities
X	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1	Street Address 2
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount	$2,050,013	USD	or Indefinite
Total Amount Sold	$2,050,013	USD
Total Remaining to be Sold	$0	USD	or Indefinite

Clarification of Response (if Necessary):

Includes pre-funded warrants to purchase up to 204,547 ADSs, each representing 500 ordinary shares, and aggregate exercise price of ADSs underlying pre-funded warrants, each exercisable for one ADS at exercise price $0.0001 per ADS.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

4

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$0	USD	Estimate
Finders' Fees	$0	USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0

USD

Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

• Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
KAZIA THERAPEUTICS LTD	/s/ John Friend	John Friend	Chief Executive Officer	2025-08-14

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

FAQ

What amount did Kazia Therapeutics (KZIA) raise in this Form D filing?

The filing reports a total offering amount of $2,050,013, and the total amount sold is $2,050,013.

What securities were offered in the KZIA offering?

The offering included equity, options/warrants, and securities to be acquired upon exercise (pre-funded warrants for ADSs).

How many investors took part in the offering?

The filing shows a total of 4 investors have already invested in the offering.

Are there sales commissions or finders' fees disclosed in the filing?

No. The Form D reports $0 for sales commissions and $0 for finders' fees.

What are the terms of the pre-funded warrants disclosed by KZIA?

The pre-funded warrants allow purchase of up to 204,547 ADSs, each ADS represents 500 ordinary shares, and each pre-funded warrant is exercisable for one ADS at an exercise price of $0.0001 per ADS.

Who signed the Form D for Kazia and when?

The Form D was signed by John Friend, Chief Executive Officer, on 2025-08-14.